Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis - Summary - MDSpire
Advertisement
Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis
To evaluate survival outcomes among patients diagnosed with peripheral T-cell lymphoma (PTCL) before and after the introduction of novel agents, specifically focusing on the impact of agents like pralatrexate, romidepsin, and brentuximab vedotin.
Key Findings:
Patients diagnosed in Era 2 (2012-2020) had significantly improved overall survival (OS) compared to Era 1 (2004-2011), highlighting the impact of novel therapies.
Median OS for PTCL-NOS or AITL increased from 15.5 months in Era 1 to 18.5 months in Era 2, indicating modest improvement.
For ALCL, median OS improved dramatically from 65.5 months in Era 1 to 114.5 months in Era 2, showcasing the effectiveness of new treatments.
Diagnosis in Era 2 was associated with a lower risk of death for both PTCL-NOS/AITL and ALCL, underscoring the need for continued advancements.
Interpretation:
Despite improvements in OS, the survival gains for PTCL-NOS and AITL remain limited, indicating an urgent need for more effective therapies to address these unmet needs.
Limitations:
The study did not analyze ALK-positive and ALK-negative ALCL separately due to data limitations, which may affect the findings' applicability.
The findings are based on retrospective data, which may have inherent biases and limit generalizability.
Conclusion:
The study highlights the urgent need for breakthrough therapies in PTCL, particularly for PTCL-NOS and AITL, where survival improvements remain modest.
by Julia Wang, Yajuan Gao, N. Nora Bennani, Yun Kyoung Tiger, Arushi Khurana, Urshila Durani, Jonas Paludo, Gita Thanarajasingam, Steven R. Hwang, Yucai Wang, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Stephen M. Ansell, Jithma P. Abeykoon
